Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

n about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not be able to commence or complete one or more of the seven clinical studies noted above due to any number of factors, including lack of regulatory approval or slower than expected patient enrollment, the risk that the addition of clinical trial sites will not result in increased enrollment, and the risk that Avid may not continue to grow its manufacturing revenue, thereby increasing cashflows, due to the loss of existing clients, or in ability to acquire new clients. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed fr
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...
(Date:5/16/2013)... ISPE announced today that ... the newly created position of Vice President of ... be responsible for stimulating ISPE’s revenue growth by ... Society’s Member-led and staff-driven business model, initiating integrated ... membership and product marketing. , “Barbara joins ISPE ...
(Date:5/16/2013)... Kitware , a leading ... new Phase II SBIR funding from the U.S. ... an open-source, high performance computing (HPC) simulation and ... researchers to select only the toolkits and applications ... or analysis tasks. , Manufacturers increasingly rely ...
(Date:5/16/2013)... On average, developing a new drug ... dollars. Despite this investment, less than 10% of drugs ... your clinical trial design optimally structured to balance time, ... Dr. Frederic Sax, Global Head of the Center for ... data, information and technology in upfront clinical trial planning ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... United Therapeutics Corporation (NASDAQ: UTHR ) (the ... market and other conditions, $210 million aggregate principal amount of ... accordance with Rule 144A under the Securities Act of 1933, ... grant to the initial purchaser of the notes an option ...
... 2011 PAT and QbD remains a field that ... released by Pharma IQ across the PAT and QbD community it ... they were not implementing PAT/QbD was due to a lack of ... once again opens its doors to industry specialists from the PAT ...
... Reportlinker.com announces that a new market research ... Nanobiotechnology: Applications and Global Markets ... The total market for nanobiotechnology products ... growing at a compound annual growth rate ...
Cached Biology Technology:United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program 2United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program 3United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program 4Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream 2Nanobiotechnology: Applications and Global Markets 2Nanobiotechnology: Applications and Global Markets 3Nanobiotechnology: Applications and Global Markets 4Nanobiotechnology: Applications and Global Markets 5Nanobiotechnology: Applications and Global Markets 6Nanobiotechnology: Applications and Global Markets 7Nanobiotechnology: Applications and Global Markets 8Nanobiotechnology: Applications and Global Markets 9Nanobiotechnology: Applications and Global Markets 10Nanobiotechnology: Applications and Global Markets 11Nanobiotechnology: Applications and Global Markets 12Nanobiotechnology: Applications and Global Markets 13
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
(Date:5/16/2013)... 17, 2013) Illustrating a commitment to the ... Gastroenterological Association (AGA) Research Foundation has announced the ... Fellowship Award recipients. Supported by the National Institute ... this new award helps underrepresented minority students to ... nutrition research. , "By establishing this new award, ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... anti-aging technologies may extend human lifespans at an unprecedented ... economic challenges, says biologist Shripad Tuljapurkar of Stanford University. ... have major implications for the global community in the ... of Population Studies, will give a talk Feb. 17 ...
... Mayr's theory of genetic revolution , introduced in 1954, ... detractors. , Mayr believed that genes interacted with one ... to an interaction of natural selection with genetic drift ... change. , Detractors of the theory object to what ...
... range of diseases in several animal species has been found ... was found most often in the blood of individuals with ... exposure. , A study on these findings was published Wednesday ... by scientists from Oregon State University, the Center for Pediatric ...
Cached Biology News:World faces challenge as life expectancies lengthen, scientist says 2World faces challenge as life expectancies lengthen, scientist says 3World faces challenge as life expectancies lengthen, scientist says 4Ernst Mayr's theory illustrated in genetic epidemiology studies 2Ernst Mayr's theory illustrated in genetic epidemiology studies 3Ernst Mayr's theory illustrated in genetic epidemiology studies 4Ocean virus identified in human blood samples 2Ocean virus identified in human blood samples 3Ocean virus identified in human blood samples 4
... Fully adjustable mixing angle, Variable speed, Digital ... a number of different sized tubes, Spillage ... cultures, keeping biological samples in suspension and ... be used in incubators up to 60C ...
... C6 Flow Cytometer System is a full featured, ... including: the C6 Flow Cytometer, CFlow Software, and ... Flow Cytometer System provides all the capabilities of ... of the price. The C6 Flow Cytometer System ...
... Mini-PROTEAN II multiscreen apparatus is used to screen ... gels. The apparatus can screen up to 40 ... the blot into strips. The apparatus includes a ... accommodate one or two 8 x 7 cm ...
Fingerprinting II Informatix cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to ...
Biology Products: